The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Verona Pharma Rises After Huge Fundraise

Fri, 17th Jul 2020 10:49

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

Homeserve, up 2.7%. The home emergency cover provider said its membership businesses, policy renewal and mid-term cancellation rates have all continued in line with historic trends in a "traditionally quieter period", spanning April to mid-July. The home repairs and improvements company added that it has felt no effects from Covid-19 and "customer satisfaction is at record highs" reflecting strong service levels during the pandemic. Homeserve has resumed mergers and acquisitions activity with a strong pipeline of targets and four profitable acquisitions completed in May and June, the most significant of these bringing 38,000 new policy customers in Spain. Walsall, England-based Homeserve continues to expect to deliver a solid performance in the year ending March 31, 2021.

----------

National Grid, up 2.0%. Deutsche Bank raised the UK power grid operator to Buy from Hold.

----------

Rio Tinto, up 1.7%. The Anglo-Australian miner left its annual guidance unchanged after posting mixed second-quarter production figures. Bauxite and iron ore output grew in the three months to June 30, though there was a double-digit fall in titanium dioxide slag production, figures from the miner showed. The FTSE 100-listed firm did edge its capital expenditure forecasts higher as the bite from Covid-19 eased and the dollar weakened. Pilbara iron ore production rose 4% year-on-year in the second quarter to 83.2 million tonnes, with shipments edging 1% higher to 86.7 million tonnes.

----------

FTSE 250 - WINNERS

----------

Renishaw, up 6.0%. The precision instruments maker raised its annual revenue forecast, but downgraded its profit estimate. Renishaw predicted revenue for the year to June 30, to be around GBP510 million. In May, it had guided for revenue in a range between GBP490 million to GBP505 million. However, Renishaw warned it will miss its annual pretax profit estimate due to GBP46 million in charges, but remains focused on cash preservation due to the Covid-19 pandemic. The company, which makes dental scanning products and precision measurement equipment, in May, had guided pretax profit for the financial year, to be in the range of GBP31 million and GBP41 million. It anticipates GBP24 million in restructuring costs and GBP22 million of fair value losses of financial instruments in financial 2020. In financial 2019, the company recorded pretax profit of GBP109.9 million on a revenue of GBP574.0 million. Adjusted pretax profit had totalled GBP103.9 million.

----------

Ninety One, up 2.2%. The money manager, formerly part of Investec, posted a double-digit climb in assets under management during its first-quarter. Assets under management rose 14% to GBP118.0 billion at June 30 from GBP103.4 billion at the end of March. The second quarter of 2020, the first quarter of Ninety One's 2021 financial year, saw equities bounce as easing Covid-19 restrictions in some areas improved risk sentiment.

---------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Verona Pharma, up 42%. The biopharmaceutical company said it has raised USD200 million in an oversubscribed private share placement and subscription. The fundraise comprises a private placement of 39.1 million American Depositary shares, each representing eight ordinary shares, at USD4.50 per ADS, and 43.1 million ordinary shares at the same issue price. Net proceeds of the financing is expected to total USD183 million, after deducting placement agent fees and estimated expenses. The issue price represents a discount of 4.7% to USD4.72 per ADS price on Wednesday. The company focused on respiratory diseases said it will use the proceeds to fund its phase 3 clinical program - Ensifentrine as a novel inhaled nebulized COPD therapy - in chronic obstructive pulmonary disease and for general corporate purposes. The trials are planned to start later in 2020.

----------

Pennant International, up 24%. The training and support services provider announced the winning of a new contract with an initial order value of GBP1.5 million. The award follows Pennant in February receiving a statement of intent for the purchase of training aids worth up to GBP5 million from a unnamed Middle East-based customer. The majority of revenue on the order is expected to be recognised in 2021 as the training aids are completed and delivered. The new contract award takes Pennant's contracted order book for 2021 to just under GBP13.5 million. Looking ahead, the group expects the customer to make further purchases, and anticipates another order to be placed either later in 2020 or early 2021.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
7 Mar 2019 11:28

DIRECTOR DEALINGS: Verona Pharma Chair David Ebsworth Buys Shares

LONDON (Alliance News) - Clinical-stage biopharmaceutical company Verona Pharma PLC said on Thursday Chair David Ebsworth bought 26,300 shares for 56.30 pence each on Wednesday.Following in

Read more
4 Mar 2019 13:35

Monday broker round-up

(Sharecast News) - RSA Insurance Group: JP Morgan downgrades to neutral with a target price of 610p.

Read more
4 Mar 2019 10:12

Verona Pharma Reports Positive Data From Lung Disease Treatment Trial

LONDON (Alliance News) - Shares in Verona Pharma PLC rose on Monday following positive data from part of a Phase Two clinical trial of a dry powder inhaler formulation of Verona's ensifentrine

Read more
14 Jan 2019 10:23

WINNERS & LOSERS SUMMARY: JD Sports Rises After Strong Christmas

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - LOSERS----------Paddy Power

Read more
14 Jan 2019 09:47

Verona Pharma's Ensifentrine COPD Study Does Not Meet Primary Endpoint

LONDON (Alliance News) - Verona Pharma PLC on Monday said its phase two clinical trial of nebulized Ensifentrine did not meet its primary endpoint but did perform better than placebo.Shares

Read more
14 Jan 2019 08:48

Verona Pharma shares plunge on latest drug trial results

(Sharecast News) - Verona Pharma shares were well into the red on Monday, after the clinical-stage biopharmaceutical company announced top-line data from its latest trial of RPL554, failing to reach its primary endpoint.

Read more
9 Jan 2019 15:44

Verona Pharma granted WHO approval for Ensifentrine name

(Sharecast News) - Clinical stage biopharmaceutical outfit Verona Pharma has been granted approval of the name Ensifentrine for its first-in-class, inhaled, dual inhibitor drug candidate RPL554 by the World Health Organisation.

Read more
17 Dec 2018 14:22

Verona Pharma initiates Phase 2 study of RPL554

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a Phase 2 clinical trial to evaluate the pharmacokinetic (PK) profile, efficacy and safety of a dry powder inhaler (DPI) formulation of 'RPL554', in patients with moderate to severe chronic obstructive pulmonary disease (COPD), on Monday.

Read more
6 Nov 2018 11:56

Verona Pharma Third-Quarter Loss Narrows On Finance Income

LONDON (Alliance News) - Verona Pharma PLC on Tuesday said its loss narrowed by two thirds in the third quarter of 2018 on increased finance income and reduced costs as it initiated a phase two of

Read more
31 Oct 2018 12:25

Verona Pharma Completes Enrollment In Clinical Trial Of RPL554

LONDON (Alliance News) - Verona Pharma PLC said Wednesday it has completed the enrollment for its Phase 2 clinical trial evaluating the effect of nebulised RPL554 as an add-on to dual therapy in a

Read more
26 Oct 2018 11:46

Verona Pharma turns in positive data from RPL554 trials

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma turned in some positive data from its pre-clinical and Phase 2a trials on its potential cystic fibrosis treatment RPL554.

Read more
1 Aug 2018 12:49

Verona Pharma Starts Phase 2 Trial For Respiratory Disease Treatment

LONDON (Alliance News) - Verona Pharma PLC said Wednesday that it started the second phase of a clinical trial of its nebulized RPL554 drug for the treatment of patients with chronic obstructive 2

Read more
8 May 2018 07:01

LONDON MARKET EARLY CALL: Stocks Called Lower As Iran Fears Boost Oil

LONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday following Monday's UK bank holiday as Chinese exports recovered at a faster pace in April amid concerns the US

Read more
26 Mar 2018 10:19

Verona Pharma Shares Rise As It Gets Good Results From RPL554 Trials

LONDON (Alliance News) - Verona Pharma PLC said Monday it has received positive top-line data from its phase 2b study for its proposed RPL554 treatment.RPL554 is a for

Read more
8 Mar 2018 13:59

DIRECTOR DEALINGS: Verona Pharma CEO Karlsson Buys 3,250 Shares

LONDON (Alliance News) - Verona Pharma PLC, a clinical-stage biopharmaceutical company, said Thursday that Chief Executive Officer Jan-Anders Karlsson purchased 3,250 ordinary

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.